1Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 case from 1992 to 2000. Am J Gastroenterel,2005,100( 1 ) : 162-168.
2Sleijfer S, Wiemer E,Verweij J. Drug insight:gastrointestinal stromal tumors( GIST)-the solid tumor model for cancer-specific treatment. Nat Clin Pract Oneol 2008 ; 5 : 102-111.
3Muzur MT, Clarr HB. Gastric stromal tumor reappraisal of histogenesis. Am J surg pathol, 1983,7:507.
4Agaimy A, Wunsch PH, Hostaedter F, et al. Minute gastric sclerosing stromd tumors( GIST tumorlet)ave common in adults and frequently Show c-KIT mutations. Am J Surg Pathol,2007,31 ( 1 ) : 113-120.
5Blay JY,Bonvalot S,Cosali P,el al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20? 21 March 2004, under the auspices of ESMO. Ann Oncol,2005,16(4) :566-578.
6Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors(GIST) during the rapy with imatinib mesylate. J Surg Oncol,2006,93 (4) : 304-311.
7DeMatteo, R. P. , Owzar, K. , Antonescu, C. R. Efficacy of adjuvant imatinib mesylate following complete resection of Iocalized, primazy gastrointestinal stromal tumor(GIST) at high risk of recurrence:The U. S. Intergroup phase Ⅱ trial ACOSOGZ9000. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium; January25-27, Orlando, Florida. 2008, Abstract.
8Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial. Lancet, 2009,373 : 1097-1104.
9George D. Demetri, MD, Margaret yon Mehren, MD, et al. MDNCCN Task Force Report:Update on the anagement of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network. April 2010.
